We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ALVAL market cap is 21.89M. The company's latest EPS is EUR -0.4665 and P/E is -2.98.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.91M | 5.1M | 2.71M | 2.83M | 6.81M |
| Operating Income | -5.13M | -3.37M | -8.48M | -12.03M | -7.18M |
| Net Income | -5.5M | -3.83M | -8.68M | -12.31M | -7.37M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 15.06M | 21.08M | 28.54M | 27.22M | 33.31M |
| Total Liabilities | 6.81M | 13.93M | 14.25M | 13.86M | 13.71M |
| Total Equity | 8.25M | 7.15M | 14.3M | 13.36M | 19.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.95M | 2.69M | -7.16M | -9.19M | -8.06M |
| Investing | -290k | -332k | -7k | -197k | -250k |
| Financing | 5.85M | 4.19M | 14.4M | 8.4M | 12.5M |
| Market Cap | 21.89M |
| Price to Earnings Ratio | -2.98 |
| Price to Sales Ratio | 3.22 |
| Price to Cash Ratio | 0.88 |
| Price to Book Ratio | 1.12 |
| Dividend Yield | - |
| Shares Outstanding | 15.79M |
| Average Volume (1 week) | 64.33k |
| Average Volume (1 Month) | 101.74k |
| 52 Week Change | -70.26% |
| 52 Week High | 5.30 |
| 52 Week Low | 1.07 |
| Spread (Intraday) | 0.04 (2.6%) |
| Company Name | Valbiotis SA |
| Address |
zi des quatre chevaliers 12f rue paul vatine paris, paris 17180 |
| Website | https://www.valbiotis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
